ReproNovo doses first participant in EU Phase 2 RPN-002 embryo implantation trial

The NORDIC study will enroll 120 participants across five European sites to test two dosing regimens of the oral oxytocin receptor antagonist in IVF and ICSI.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.